FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2083668359> ?p ?o ?g. }

• W2083668359 endingPage "70" @default.
• W2083668359 startingPage "59" @default.
• W2083668359 abstract "The in vivo effects of irindalone, a newly developed serotonin2 (5-HT2) antagonist, have been investigated in comparison with a series of reference compounds. Irindalone potently antagonizes the pressor response induced by 5-HT in pithed rats, but has a 173 times weaker effect against the α1-adrenoceptor agonist phenylephrine. Irindalone is relatively weak in rat models detecting central 5-HT2 antagonism, that is, inhibition of quipazine- or I-5-HTP plus citalopram-induced head twitches, inhibition of I-5-HTP plus citalopram-induced increases of flexor reflexes, and inhibition of the discriminative stimulus properties induced by d-LSD. Furthermore, it displaces in vivo 3H-ketanserin binding in frontal cortex. Irindalone weakly antagonizes the flexor reflex stimulated by the α1-adrenoceptor agonist St 587. No dopamine receptor inhibition is detected in the methylphenidate gnawing test in mice. High bioavailability is indicated by the identical ED50 values obtained in the head twitch model after s.c. and p.o. administration. The activity profile of irindalone resembles that of ketanserin except in two characteristics: ketanserin has greater potency than irindalone as an antagonist in the 5-HTP-induced flexor reflex, but has a shorter duration of action. The effect of irindalone is stereoselective, since its opposite enantiomer Lu 21-099 is almost inactive in the models for central and peripheral 5-HT2 receptor antagonism. Finally, the effect of repeated treatment with irindalone (18 μmol/kg, p.o., twice daily for 2 weeks) on inhibition of quipazine-induced head twitches was studied. Two days after the last dose, the potency for inhibiting quipazine was unchanged, indicating that no tolerance to 5-HT2 receptor antagonism develops using this dose regimen. It is concluded that irindalone is a potent 5-HT2 antagonist with preferential effects at peripheral sites." @default.
• W2083668359 created "2016-06-24" @default.
• W2083668359 creator A5019978427 @default.
• W2083668359 creator A5020731322 @default.
• W2083668359 creator A5037459343 @default.
• W2083668359 creator A5042606326 @default.
• W2083668359 creator A5043710094 @default.
• W2083668359 creator A5047726476 @default.
• W2083668359 creator A5086437257 @default.
• W2083668359 date "1989-01-01" @default.
• W2083668359 modified "2023-10-02" @default.
• W2083668359 title "In vivo pharmacology of irindalone, a 5-HT2receptor antagonist with predominant peripheral effects" @default.
• W2083668359 cites W1967189169 @default.
• W2083668359 cites W1988733687 @default.
• W2083668359 cites W1991077292 @default.
• W2083668359 cites W1997626952 @default.
• W2083668359 cites W2000317490 @default.
• W2083668359 cites W2000579472 @default.
• W2083668359 cites W2005395166 @default.
• W2083668359 cites W2011512172 @default.
• W2083668359 cites W2011857210 @default.
• W2083668359 cites W2014849557 @default.
• W2083668359 cites W2015547448 @default.
• W2083668359 cites W2022199444 @default.
• W2083668359 cites W2026473192 @default.
• W2083668359 cites W2060172635 @default.
• W2083668359 cites W2061837419 @default.
• W2083668359 cites W2118065688 @default.
• W2083668359 cites W2148208190 @default.
• W2083668359 cites W2167821659 @default.
• W2083668359 doi "https://doi.org/10.1002/ddr.430160107" @default.
• W2083668359 hasPublicationYear "1989" @default.
• W2083668359 type Work @default.
• W2083668359 sameAs 2083668359 @default.
• W2083668359 citedByCount "10" @default.
• W2083668359 crossrefType "journal-article" @default.
• W2083668359 hasAuthorship W2083668359A5019978427 @default.
• W2083668359 hasAuthorship W2083668359A5020731322 @default.
• W2083668359 hasAuthorship W2083668359A5037459343 @default.
• W2083668359 hasAuthorship W2083668359A5042606326 @default.
• W2083668359 hasAuthorship W2083668359A5043710094 @default.
• W2083668359 hasAuthorship W2083668359A5047726476 @default.
• W2083668359 hasAuthorship W2083668359A5086437257 @default.
• W2083668359 hasConcept C126322002 @default.
• W2083668359 hasConcept C134018914 @default.
• W2083668359 hasConcept C150903083 @default.
• W2083668359 hasConcept C170493617 @default.
• W2083668359 hasConcept C185592680 @default.
• W2083668359 hasConcept C207001950 @default.
• W2083668359 hasConcept C2775864247 @default.
• W2083668359 hasConcept C2776885963 @default.
• W2083668359 hasConcept C2777383412 @default.
• W2083668359 hasConcept C2777448245 @default.
• W2083668359 hasConcept C2777785214 @default.
• W2083668359 hasConcept C2777952589 @default.
• W2083668359 hasConcept C2778938600 @default.
• W2083668359 hasConcept C2781073084 @default.
• W2083668359 hasConcept C42533223 @default.
• W2083668359 hasConcept C53910766 @default.
• W2083668359 hasConcept C55493867 @default.
• W2083668359 hasConcept C71924100 @default.
• W2083668359 hasConcept C83974742 @default.
• W2083668359 hasConcept C84393581 @default.
• W2083668359 hasConcept C86803240 @default.
• W2083668359 hasConcept C98274493 @default.
• W2083668359 hasConceptScore W2083668359C126322002 @default.
• W2083668359 hasConceptScore W2083668359C134018914 @default.
• W2083668359 hasConceptScore W2083668359C150903083 @default.
• W2083668359 hasConceptScore W2083668359C170493617 @default.
• W2083668359 hasConceptScore W2083668359C185592680 @default.
• W2083668359 hasConceptScore W2083668359C207001950 @default.
• W2083668359 hasConceptScore W2083668359C2775864247 @default.
• W2083668359 hasConceptScore W2083668359C2776885963 @default.
• W2083668359 hasConceptScore W2083668359C2777383412 @default.
• W2083668359 hasConceptScore W2083668359C2777448245 @default.
• W2083668359 hasConceptScore W2083668359C2777785214 @default.
• W2083668359 hasConceptScore W2083668359C2777952589 @default.
• W2083668359 hasConceptScore W2083668359C2778938600 @default.
• W2083668359 hasConceptScore W2083668359C2781073084 @default.
• W2083668359 hasConceptScore W2083668359C42533223 @default.
• W2083668359 hasConceptScore W2083668359C53910766 @default.
• W2083668359 hasConceptScore W2083668359C55493867 @default.
• W2083668359 hasConceptScore W2083668359C71924100 @default.
• W2083668359 hasConceptScore W2083668359C83974742 @default.
• W2083668359 hasConceptScore W2083668359C84393581 @default.
• W2083668359 hasConceptScore W2083668359C86803240 @default.
• W2083668359 hasConceptScore W2083668359C98274493 @default.
• W2083668359 hasIssue "1" @default.
• W2083668359 hasLocation W20836683591 @default.
• W2083668359 hasOpenAccess W2083668359 @default.
• W2083668359 hasPrimaryLocation W20836683591 @default.
• W2083668359 hasRelatedWork W2021266729 @default.
• W2083668359 hasRelatedWork W2031422462 @default.
• W2083668359 hasRelatedWork W2042006386 @default.
• W2083668359 hasRelatedWork W2078021530 @default.
• W2083668359 hasRelatedWork W2083668359 @default.
• W2083668359 hasRelatedWork W2094279584 @default.
• W2083668359 hasRelatedWork W2095312450 @default.

• next